Robbins LLP Reminds CERE Stockholders With Large Losses to Contact the Firm for Information About the Class Action Lawsuit on Behalf of Former Cerevel Therapeutics Holdings, Inc. Shareholders

Core Viewpoint - A class action has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, alleging violations of the Securities Exchange Act of 1934 related to misleading investors during a secondary stock offering and subsequent merger announcement [1][2][3]. Group 1: Allegations and Impact - The complaint claims that Cerevel's secondary offering documents omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price until the merger was announced [2]. - Bain Capital, as Cerevel's controlling shareholder, allegedly purchased shares at the depressed price while possessing nonpublic information about AbbVie's acquisition interest, leading to a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share [2]. - The action also seeks damages for investors who held shares as of January 8, 2024, due to misleading statements in Cerevel's January 18, 2024 Proxy statement regarding the nature and timing of AbbVie's interest [3]. Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by June 3, 2025, with the lead plaintiff representing other class members in the litigation [4]. - Shareholders do not need to participate actively in the case to be eligible for recovery, allowing them to remain absent class members if they choose [4].